Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameAcotec-B
Stock Code06669
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities我們是中國創新醫療器械企業,以「介入無植入」為理念,提供血管疾病治療方案,研發藥物塗層球囊(DCB)及血栓抽吸導管等介入醫療器械。
Listing Date2021-08-24
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國北京北京經濟技術開發區宏達北路16號1幢4至5層
Business Address (Hong Kong)香港德輔道中188號金龍中心14樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websiteacotec.cn
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 23.80 / shares
Offer Price RangeFinal offer price only, no range
Lot Size1,000 shares
Entry ThresholdHK$ 23,800
Par ValueTo be extracted
Offer Period2021-08-12 to 2021-08-17
Global Offering Shares68,633,000 shares
HK Public Offer Shares (Initial)6,864,000 shares (10.0%)
Public Offer Lots (Initial)6,864lots (Pool A3,432lots,Pool B3,432lots)
International Placing Shares (Initial)61,769,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO313,389,171 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share49.9%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 1,633,465,400

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 1,000 HK$ 23,800
2 lots 2,000 HK$ 47,600
3 lots 3,000 HK$ 71,400
4 lots 4,000 HK$ 95,200
5 lots 5,000 HK$ 119,000
6 lots 6,000 HK$ 142,800
7 lots 7,000 HK$ 166,600
8 lots 8,000 HK$ 190,400
9 lots 9,000 HK$ 214,200
10 lots 10,000 HK$ 238,000
12 lots 12,000 HK$ 285,600
14 lots 14,000 HK$ 333,200
16 lots 16,000 HK$ 380,800
18 lots 18,000 HK$ 428,400
20 lots 20,000 HK$ 476,000
25 lots 25,000 HK$ 595,000
30 lots 30,000 HK$ 714,000
35 lots 35,000 HK$ 833,000
40 lots 40,000 HK$ 952,000
45 lots 45,000 HK$ 1,071,000
50 lots 50,000 HK$ 1,190,000
60 lots 60,000 HK$ 1,428,000
70 lots 70,000 HK$ 1,666,000
80 lots 80,000 HK$ 1,904,000
90 lots 90,000 HK$ 2,142,000
100 lots 100,000 HK$ 2,380,000
150 lots 150,000 HK$ 3,570,000
200 lots 200,000 HK$ 4,760,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
250 lots 250,000 HK$ 5,950,000
300 lots 300,000 HK$ 7,140,000
350 lots 350,000 HK$ 8,330,000
400 lots 400,000 HK$ 9,520,000
450 lots 450,000 HK$ 10,710,000
500 lots 500,000 HK$ 11,900,000
600 lots 600,000 HK$ 14,280,000
700 lots 700,000 HK$ 16,660,000
800 lots 800,000 HK$ 19,040,000
900 lots 900,000 HK$ 21,420,000
1,000 lots 1,000,000 HK$ 23,800,000
1,500 lots 1,500,000 HK$ 35,700,000
2,000 lots 2,000,000 HK$ 47,600,000
2,500 lots 2,500,000 HK$ 59,500,000
3,432 lots 3,432,000 HK$ 81,681,600

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 2.69B
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +261%

Valuation & Financials

Market Cap (at Offer Price)HK$ 7,458,662,269
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status亏损人民幣44.3百萬元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 105
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 20192020
Revenue 124,910193,975
Cost of sales -18,979-30,195
Gross profit 105,931163,780
Other income and gains, net 2,9644,645
Selling and distribution expenses -36,266-32,581
Administrative expenses -20,972-72,112
Operating profit 26,708-31,447
Net finance costs -3,603-12,845
Profit before tax 23,105-44,292
Income tax expense 00
Profit for the year 23,105-44,292
Profit attributable to owners 23,105-43,842
Balance Sheet
Item 201920202021-03
Cash and cash equivalents 31,524147,097
Trade and bills receivables 4,43729,518
Inventories 32,84228,538
Total current assets 73,229218,241
Total assets 112,239272,941
Total current liabilities 59,189404,124
Total liabilities 96,208123,115
Total equity 16,031149,826
Equity attributable to owners 16,031149,496
Interest-bearing borrowings 020,000144,855
Cash Flow Statement
Item 201920202021-03
Net cash from operating activities 19,856-8,765
Net cash from investing activities -2,317-17,735
Net cash from financing activities -3,190142,520
Net increase in cash 14,349116,020
Depreciation of PP&E 2,001937873
Depreciation of right-of-use assets 1,5874,1701,285
Amortisation of intangible assets 31025493
Purchase of PP&E -2,301-18,506-3,742
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 17.6
First Day OpenHK$ 18.32
First Day Change-26.05%
First Day Volume31056400.0
First Day Turnover552859000.0
Use of Proceeds
1、32%(或約489.30百萬港元)將被分配予我們的核心產品; 2、23%(或約351.70百萬港元)將被分配予我們現有產品管線中余下的24款產品; 3、7%(或約107.0百萬港元)將用于擴大生產能力及強化制造能力; 4、24%(或約366.90百萬港元)將獲分配用于為通過(其中包括)內部研發、合作、合并及收購、授權引進或股權投資等方式擴大我們的產品組合提供資金; 5、8%(或約122.30百萬港元)將用于我們的營運資金及一般企業用途; 6、6%(或約91.70百萬港元)將用于償還2021年1月來自硅谷銀行的貸款。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Overall Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894
Joint Bookrunners (4)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 VALUABLE CAPITAL LIMITED CE AUL711
Joint Lead Managers (4)
Morgan Stanley Asia Limited CE AAD291 CHINA INTERNATIONAL CAPITAL CORPORATION HONG KONG SECURITIES LIMITED CE AEN894 CHINA MERCHANTS SECURITIES (HK) CO., LIMITED CE AAI650 VALUABLE CAPITAL LIMITED CE AUL711

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Athos Asia Event Driven Master Fund 38,817,800 HKD — 2.38% — 6 months 2022-02-24
2 CPE Investment Wu Limited 77,659,400 HKD — 4.75% — 6 months 2022-02-24
3 Dymon Asia Capital (Singapore) Pte. Ltd. 38,817,800 HKD — 2.38% — 6 months 2022-02-24
4 Perseverance Asset Management International (Singapore) Pte. Ltd. 77,659,400 HKD — 4.75% — 6 months 2022-02-24
5 Primeone Luck Limited 38,817,800 HKD — 2.38% — 6 months 2022-02-24
6 The Valliance Fund 77,659,400 HKD — 4.75% — 6 months 2022-02-24
7 保银资产管理有限公司 38,817,800 HKD — 2.38% — 6 months 2022-02-24
8 达观国际有限公司 77,659,400 HKD — 4.75% — 6 months 2022-02-24
9 汇添富基金管理股份有限公司 155,342,600 HKD — 9.51% — 6 months 2022-02-24
10 盘京港景投资基金 38,817,800 HKD — 2.38% — 6 months 2022-02-24
11 新里程医院集团有限公司 38,817,800 HKD — 2.38% — 6 months 2022-02-24
12 易方达基金管理有限公司 38,817,800 HKD — 2.38% — 6 months 2022-02-24
13 中国国际金融股份有限公司 77,659,400 HKD — 4.75% — 6 months 2022-02-24

Directors & Management

PositionChinese nameEnglish Name
Chairman李靜—
Company Secretary李晨、李菁怡—
No director data available.

Major Shareholders

Major Shareholders & Holdings緊隨全球發售完成後,CA Medtech持有本公司50.61%股份,為控股股東;李靜女士被視為持有17.53%股份。
About this page

This page shows Acotec-B (06669) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect